Randomized double-blind trial of intravenous ferric carboxymaltose with or without epoetin zeta to prevent perioperative red blood cell transfusion in hip fracture (PAHFRAC)

Phase 3, randomised, double-blind trial of ferric carboxymaltose and epoetin alfa or beta in hip fracture, osteoporosis and anemia (2 arms), sponsored by Máximo Bernabeu Wittel. Primary endpoints: Perioperative red blood cell transfusion rate and Number of red blood cell units transfused. Started Apr 2010; status: completed.